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Department of Chemistry and Biochemistry
By
Symone Crowder
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ABSTRACT
Photodynamic therapy (PDT) is considered to be a potential replacement for traditional
methods of chemotherapy. It includes the administration of photosensitizing agents (PS),
which generate reactive oxygen species (ROS) upon excitation at a specific wavelength. With
new outlooks and techniques, cancer research is advancing each day. It has allowed the
progress of several theranostic drug delivery systems (DDS) exploring the area of
nanomedicine.2 In the present work, a Rhodamine derivative, Rhodamine 6G (R6G) was used
as the PS. In general, rhodamine compounds undergo cytotoxic reactions on photoexcitation
by electron transfer reactions with folic acid within cells, making them a favorable PS.
However, rhodamines often experience poor water solubility which limits their applications
in biological environments. Additionally, the process of PDT requires a high accumulation
of photosensitizers. To overcome the challenge of aqueous compatibility of rhodamine
compounds as well as retaining its specific functioning in cells at a reduced optimum
concentration, this project focused on developing a nanocarrier system using gold
nanoparticles (GNPs) to help deliver those dyes to the cancer targets. The GNPs were
synthesized with a particle size ranging from 16 to 30 nm. Towards the aim to understand
the photodynamic inactivation of cancer cells, absorption and fluorescence spectroscopic
techniques were utilized. Dynamic Light Scattering (DLS) spectroscopy has been used to
measure the hydrodynamic size of the nanoparticles. UV-Vis and fluorescence spectroscopy
analyzed the nanocomposite with the rhodamine derivative and studied the immobilization
over time. The 24-hour experiments provided a route for GNP conjugated rhodamine dye
towards using PDT as the most viable method.
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1. Introduction
When it comes to treating cancer, the process is synonymous with chemotherapy,
radiation, and a taxing battle that could cause severe detriment to the patient long before
they get better. Chemotherapy in combination with radiation was first used as a treatment
option in the 1940’s8, but the substantial effects the treatment has on the healthy cells of
the body, as well as the limitations the treatment has with late-stage cancers has always left
the door open to research new methods of treatment. In the years since then, different
efforts have been focused on cancer vaccines as well as drugs that diffuse into cancerous
cells. Photodynamic therapy (PDT) is an additional prospect that hopes to one day allow
for the phasing-out of chemotherapy and radiation as the primary option for cancer
treatment.
The name “Photodynamic therapy” itself was first coined by the German scientist
and professor Herman Von Tappeiner in the year 1907. The word was then used to describe
the effect that the presence or absence of light had on “oxygen-dependent
photosensitization”.2 While the field of what would now be considered “phototherapy”
dates back all the way to the ancient Egyptians,2 the discovery of photodynamic therapy
itself was somewhat of an accident. Oscar Raab, a student of Von Tappeiner’s, was tasked
with studying the effects of an acridine chemical against malaria samples when he noted
that what marked the change in the effectiveness of the chemical was higher on the day
that a thunderstorm had caused drastically different light conditions for the experiment.2
This theory was expanded upon until they proved conclusively that light had an
advantageous effect on the acridine chemical, and further that it was not the light itself, but
the effects of fluorescence within biological systems.² The study concluded with the
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incomplete hypothesis that there was a transfer of energy from light to chemical, similar to
photosynthesis, which increased the effectiveness of the drug.² Von Tappeiner himself
furthered this theory with use of the photosensitizer, eosin, for the treatment of skin cancer,
concluding that this process also needed oxygen.² This discovery brought together all of
the pieces to define photodynamic therapy as it is still known to this day.
The necessity of oxygen presence for photodynamic therapy comes from the nature
of fluorescence itself. Fluorescence is observed when the correct wavelength of light causes
a stable molecule to enter an excited state. A short period of excitation is known as a singlet
state, while a longer excitation time is known as the triplet state. This triplet state is where
the excited molecule becomes the “photo-active species,” which interacts with an oxygen
molecule to produce singlet oxygen. Singlet oxygen leads to photo-oxidation within a cell,
eventually leading to the cell’s death.
Modern advancements in photodynamic therapy have begun utilizing nanoparticles
coated by photosensitizer drugs. The photosensitizer drugs used in this scenario serve three
functions. They first increase the solubility of nanoparticles in water, allowing for greater
passage of the solution through the body. Second, photosensitizer drugs allow the
nanoparticles to accumulate within cancerous cells so that they may be targeted
independently of healthy cells. Finally, they determine the required wavelength for the light
which will be used to excite the nanoparticles. This excitation may also be used to cause
the nanoparticles within the cancerous mass or cancer cells to generate heat, causing the
cancerous cells to die via photothermal therapy.11 Photodynamic therapy, in contrast, is
dependent on the formation of reactive oxygen species (ROS). PDT has yet to be used in a
large-scale capacity, with one aspect preventing the widespread use of Gold Nanoparticles
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(GNPs) for photodynamic therapy being the unknown time frame of viability for
synthesized GNPs.
The present work synthesizes GNPs

for subsequent incubation with

photosensitizer, Rhodamine 6G (R6G), in order to establish a timeline of viability for
nanoparticle-conjugated

photosensitizers.

Knowing

these

parameters

will

help

photodynamic therapy become a more plausible option within an industry or hospital
setting, bringing the field even closer to public use.
In literature, methods for the sizing of gold nanoparticles based on their UV-Visible
(UV-Vis) absorbance have been established.⁴ PDT itself can utilize absorbances in both
the IR and “Near IR” region on the electromagnetic spectrum.9 Throughout this project,
UV-Vis is used extensively in accordance with this. Both size estimations and capability
for photodynamic therapy were established this way, culminating in the incubation study
wherein it was found that gold nanoparticles when combined with photosensitizer remain
viable for approximately 48 hours.

2. Materials:
Chemicals Used:
Gold (III) chloride was purchased from Sigma Aldrich. Trisodium citrate dihydrate
was purchased from Spectrum Chemical Corporation. Deionized (DI) water from filtered
and collected in-lab. Rhodamine 6G purchased from Acros Organics.
Instruments Used:
Thermo Fisher scientific Epure water filtration system, Shimadzu UV-2600 UVVis Spectrophotometer, Perkin Elmer LS 55 Fluorescence Spectrometer, Malvern Nano-
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Zs Zetasizer, JEOL JSM-7600 F Field Emission Scanning Electron Microscope.

3. Methods:
Synthesis of Gold Nanoparticles (GNPs)
GNPs were synthesized using methods established in published literature.⁴ 500 µL
of 3.37 x 10-2 M HAuCl4 were added to a 100 mL round bottom flask containing 50 g
deioinized (DI) water. The solution was placed on a hot plate on high heat and allowed to
stir until boiling. Next, 1 mL of 3.54 x 10-2 M trisodium citrate solution was added to the
boiling solution. Upon color change, the heat was turned off and the solution was allowed
to stir until cool.
Combination of GNP with Rhodamine 6G for incubation
The rhodamine 6G (R6G) photosynthesizer was used for incubation in
concentrations ranging from 1.67 × 10-7 M R6G in GNP to 1.67 × 10-5 M R6G in GNP.
These concentrations were 1.67 × 10-7 M R6G in GNP, 5.00 × 10-7 M R6G in GNP, 1.67
× 10-6 M R6G in GNP, 3.33 × 10-6 M R6G in GNP, 8.33 × 10-6 M R6G in GNP, and 1.67
× 10-6 M R6G in GNP. Control data was also collected at these same concentrations for
R6G in water. Each solution was made just before subsequent UV-Vis or fluorescence
spectroscopies were collected in order to ensure the least time possible between creation
and the “initial” measurement of each sample. Subsequent incubation times were then
based on each individual time of combination with R6G.
UV-Vis and Fluorescence Spectroscopies
UV-Vis data was collected using a Shimadzu UV-2600 UV-Vis Spectrophotometer
to obtain absorption spectra for each sample from 200-900 nm.
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Fluorescence spectroscopy was conducted on a Perkin Elmer LS 55 Fluorescence
Spectrometer. The excitation wavelength was set as 526 nm, corresponding to Rhodamine
6G’s λmax.13 The excitation slit was set as 5 nm and the emission slit was set as 2.5 nm,
with the spectra being collected on the interval 531-750 nm.
When performed in tandem, UV-Vis and fluorescence spectra were taken in
alternation with each other, ensuring that the initial measurements, as well as all subsequent
incubation readings were as accurate as possible.
Characterization of GNP Solution by Dynamic Light Scattering
Dynamic Light Scattering (DLS) was used to characterize the approximate size of
nanoparticles within solution. DLS operates on the principle of Rayleigh light scattering
through a solution with suspended spherical particles to measure the diameter of particles
smaller than the wavelength of visible light.7 This principle makes DLS a great technique
for the characterization of the spherical nanometer-sized samples synthesized in this
project. For DLS measurements, approximately 10 mL of GNP sample (without R6G) was
centrifuged and subsequently filtered through a 0.2 µm microfilter, from which a 1 mL
sample was tested. Each DLS solution was set to run in three trials, creating 9 graphs per
sample and 3 error source reports for a total of 12 graphs per GNP solution. All data was
collected using a Malvern Nano-Zs Zetasizer.

4. Results and Discussion:
Characterization of synthesized Gold Nanoparticles (GNPs)
The GNPs synthesized following the methods described in Section 3 were
characterized using steady-state UV-Vis spectroscopy. The characteristic surface plasmon
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resonance spectrum profile for spherical nanometals is depicted in Figure 1a-c with
absorption band maxima or wavelengths (λmax) in the range of 518 – 524 nm.

[4]

Figure 1a-c: Steady-state absorption spectra for the synthesized gold nanoparticles (GNPs)
at (a) λmax = 524 nm, (b) λmax = 521 nm, and (c) λmax = 518 nm.
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Figure 2a-c shows the reddish color indicative of GNP synthesized within these
wavelengths. The variation in the λmax depends on several factors such as the molar volume
or the mole fraction of citrate added or the time at which the citrate salt is added while the
acid was stirring at a boiling temperature.

Figure 2 a-c: The reddish colors for the characteristic UV-Vis spectra band maxima for
various synthesized GNPs.
The estimated diameter of GNPs can be determined using λmax from the absorption
spectra and the equation Y = 2.99 X -1539, where Y is the GNP diameter in nanometers
(nm) and X refers to λmax in nm. The equation is based on a standard linear plot showing
the correlation between the estimated GNP diameter from Transmission Electron
Microscopy (TEM) measurements and band maxima data obtained from UV-Vis as
reported by Ghosh et al.4

Based on this equation, the particle size (diameter) for our

synthesized GNPs is estimated to be approximately 27.76 nm for the sample with a λmax of
524 nm, 18.79 nm for λmax of 521 nm and 9.82 nm for λmax of 518 nm.
The synthesized GNPs were then characterized through Dynamic Light Scattering
(DLS) technique to more accurately determine their hydrodynamic particle size. Figure 3a8

b shows the size distribution spectra for two GNP samples. The GNP sample with
absorption maximum band at 521 nm has an average diameter of ~21 nm (Figure 3a) while
the sample with λmax at 518 nm is ~14 nm and (Figure 3b). While these DLS measurements
are more accurate, they are relatively comparable to the particle sizes estimated earlier
through UV-Vis. The particle sizes as indicated by DLS are in correlations to the previously
published works4,13 and corroborates that the shorter the λmax the smaller the particle size.

Figure 3a-b: Size distribution of GNP solutions with λmax at (a) 521 nm and (b) 518 nm.
All measurements were taken using Malvern Nano-Zs Zetasizer.
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Exploring the photosensitizer (PS), Rhodamine 6G (R6G)
To understand the efficiency of R6G in nanoparticle conjugate drug delivery, the
photosensitizing effect of the molecule was studied through a series of incubations in
GNPs. It is important to determine the stability of R6G in the absence of GNP in order to
compare and understand its effectiveness as a photosensitizer upon GNP conjugation.

Figure 4a-f: UV-Vis spectra for the control, R6G in in DI water at various concentrations
and time. R6G concentrations are 1.67 × 10-7 M, 5.00 × 10-7 M, 1.67 × 10-6 M R6G, 3.33
× 10-6 M R6G, 8.33 × 10-6 M, and 1.67 × 10-6 M, respectively. Incubation times are 0 hours
(initial), 1 hour, 20 hours, 45 hours, 5 days, and 6 days, respectively. Wavelength is in nm.
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Figures 4a-4f show the control data (R6G in DI water only) taken at the same R6G
concentrations and time used for the photosensitizer-gold nanoparticle conjugates the
incubation time study. The data show that independent of PS concentration or incubation
time, R6G is stable as indicated by its characteristic absorbance peak at 526 nm (λmax).
The stability of the PS is, however, altered by its conjugation with gold nanoparticle
solution. This effect was studied experimentally at various R6G concentrations in GNP and
incubation times using UV-Vis and fluorescence spectroscopies. Upon addition of the
photosensitizer to GNP solutions, color changes are observed in the vials from the standard
reddish color of the GNP solution to a blue or violet color depending on R6G
concentrations as seen in Figure 5. Over time, all GNPs will aggregate and fall out of
solution (black solid particles) turning the solutions clear. The color changes are in
accordance with the UV-Vis analysis, which suggests a loss of viability for use in PDT.

Figure 5a-b: Gold nanoparticle solutions during incubation study with increasing R6G
concentration from left to right. 5a was captured 2022/06/06 11:00 and 5b was captured
2022/06/07 14:29.
Figure 6a-f shows the behavior of a R6G conjugated GNP solution over time.
Significant absorbance shifts of particular particle solutions from their original λmax can be
seen most prevalently in the initial reading (Figure 6a) and after 1 hour (Figure 6b), 20
hours (Figure 6c), and 45 hours (Figure 6d).
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Figure 6a-f: UV-Vis spectra for the six-day incubation of various concentrations of R6G
in GNP solution between wavelengths 200-900 nm. Peak absorbance for the GNP solution
synthesized on 2022/05/18 was 524 nm indicating a particle size of 27.76 nm (±1%) in
diameter before combination with R6G.4
Observance of absorbance peak shifts from the initial λmax at 524 nm (Figure 1a) to
a higher wavelength indicated the concentrations of R6G that were best suited to complex
with the GNP solution. These concentrations were 1.67 × 10⁻⁶ M R6G in GNP and 3.33 ×
12

10⁻⁶ M R6G in GNP. Similar peak shifts were not observed at incubation times longer than
45 hours (Figures 6e-f), which may be due to the visible precipitation of aggregated
particles indicating a loss of viability. Due to these observations, subsequent incubation
studies were performed between 0 and 48 hours with an absorbance reading taken every
hour.
The first reduced interval incubation study was completed within the first 2 hours
of mixing of R6G with GNP (Figures 7a-7c). This experiment again showed absorbance
shifts in the complexes most capable of conjugating with Rhodamine 6G. This time,
however, the concentrations 1.67 × 10⁻⁶ M R6G in GNP, 3.33 × 10⁻⁶ M R6G in GNP, 8.33
× 10⁻⁶ M R6G in GNP, and 1.67 × 10⁻⁵ M R6G in GNP each showed absorbance shifts
(blue-shifted), however the absorbance peak was lower than the peak prior to R6G addition
(i.e. GNP solution only . R6G-GNP conjugation occurs when there is a blue-shift upon
addition of R6G to GNP resulting in a higher absorbance peak than that of GNP only and
therefore a new maximum band (λmax). This effect is observed for only the 3.33 × 10⁻⁶ M
R6G in GNP solution (≤ 45 hours) with its new peak absorbance at λmax between 680 nm
to 705 nm (Figures 7a-c) rather than at 521 nm, characteristic of the GNP solution with no
R6G added.
Over time (> 45 hours), the appearance of a new red-shifted absorption peak is
observed for 3.33 × 10⁻⁶ M R6G in GNP (Figures 6e-f). This change from blue to red
shifted peaks indicates that the GNPs are aggregating with R6G causing the absorbance of
the solution to resemble the established λmax in the control data (Figures 4a-f). This analysis
is consistent with the color changes and precipitation of the black solid aggregates visually
observed in the vials as mentioned earlier (Figure 5a-b).
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Figure 7a-c. Shortened incubation of R6G in GNP solution taken between wavelengths
200-900 nm. Peak absorbance for the GNP solution synthesized on 2022/05/31 and
incubated on 2022/06/02 was 521 nm, indicating a particle size of 18.79 nm (±1%) in
diameter before combination with R6G.
These UV-vis readings were taken in tandem with the fluorescence spectroscopy
readings shown in Figures 8a-c, which also show an absorbance shift over time. This shift
in absorbance indicates that while the λmax of the lower concentrated GNP solutions had
not changed, there was still some level of conjugation occurring because of the change in
peak emission of the measured samples. It should be noted that the full extent of the data
cannot be seen due to the instrument detection limit. This led to the use of an alternate
fluorimeter in order to continue experimentation.
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Figure 8. Fluorescence spectroscopy data for GNP solution synthesized on 2022/05/31,
taken in tandem with the UV-Vis measurements in Figure 7. 1.67 x 10-7 M - 3.33 ×10-6 M
R6G in GNP.
A similar incubation study was conducted on a GNP solution with λmax at 518 nm
(Figure 1c) and hourly time intervals up to 24 hours, seen as Figures 9a-9c. This study
showed results consistent with the previous incubation study (Figures 7a-7c) with the
concentrations 1.67 × 10⁻⁶ M R6G in GNP, 3.33 × 10⁻⁶ M R6G in GNP, 8.33 × 10-6 M
R6G in GNP, and 1.67 × 10-5 M R6G in GNP, each showing absorbance shifts with no
change in λmax. Like before, only the 3.33 × 10-6 M R6G in GNP solution resulted in a
true change in λmax. The data indicates a significant absorbance decrease and aggregation
increase between 2 and 24 hours, suggesting the PS-GNP conjugate may be most viable
for up to two hours.
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Figure 9a-c. Shortened incubation of R6G in GNP solution. UV-Vis measurements were
taken between wavelengths 200-900 nm. This GNP solution was synthesized on
2022/06/06 had a peak absorbance at 518 nm indicating a particle size of 9.82 nm (±1%)
in diameter before combination with R6G. Incubation studies were performed on
2022/06/07.
Fluorescence incubation study for this R6G-GNP conjugate was also conducted but
was inconclusive due to saturation of the data; further studies are underway on this aspect.
Conclusion:
Overall, we were able to synthesize GNP of diameter 16-28 nm as indicated by UVVis and DLS results. The small particle size enhanced the surface activity of the
nanoparticles when conjugated with the photosensitizer, R6G. The steady-state absorption
analysis indicated that the most effective concentration of Rhodamine 6G in GNP solution
was 3.33 × 10-6 M. This concentration of R6G with conjugated GNP solution is only viable
within the first 48 hours of R6G addition. Future studies will involve continued
16

fluorescence analysis on various R6G-GNP conjugates as well as TEM imaging to better
determine the particle size of GNPs themselves. Analysis of the in vivo effects of these
photosensitizer conjugate systems is necessary in order to explicate the efficacy and
specificity of the established GNP conjugates in aggregating within cancerous cells
towards photodynamic therapy.
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